Valuation: Pharmadrug Inc.

Market Cap 1.34M 964K 835K 783K 714K 91.96M 1.36M 9.21M 3.6M 46.05M 3.62M 3.54M 154M P/E 2024
-1.31x
P/E 2025 -4.23x
Enterprise Value 2.84M 2.04M 1.77M 1.66M 1.51M 195M 2.89M 19.5M 7.62M 97.54M 7.67M 7.5M 325M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
77.22%
Yield 2024 *
-
Yield 2025 -
1 day-39.39%
1 week+8.11%
Current month+26.98%
1 month+45.99%
3 months-9.09%
6 months+9.59%
Current year-10.11%
1 week 0.01
Extreme 0.00506
0.01
1 month 0
Extreme 0.0032
0.01
Current year 0
Extreme 0.0024
0.02
1 year 0
Extreme 0.0024
0.02
3 years 0
Extreme 0.0022
0.06
5 years 0
Extreme 0.0022
0.49
10 years 0
Extreme 0.0022
2.15
Manager TitleAgeSince
Director of Finance/CFO 50 2023-10-19
Director TitleAgeSince
Director/Board Member 82 2016-12-19
Chairman - 2024-02-26
Change 5-day change 1-year change 3-year change Capi.($)
-39.39%+8.11% - - 963K
-1.61%+0.77%+34.14%+101.83% 105B
-1.27%-1.05%+61.80%+154.57% 55.88B
-0.34%-0.34%+4.59%+270.00% 24.12B
-0.78%-0.42%-13.12%-14.11% 8.28B
-1.04%+3.55%-30.67%-25.18% 7.75B
-0.48%-3.46%-11.56%-22.27% 6.69B
+0.48%+0.43%+18.27%+17.54% 6.16B
-1.41%-4.96%-5.85%+18.48% 5.01B
-0.59%-0.40%-6.15%-4.99% 3.75B
Average -4.62%+1.78%+5.72%+55.10% 24.75B
Weighted average by Cap. -1.22%+4.94%+30.48%+114.81%

Financials

2024 2025
Net sales - -
Net income -793K -570K -494K -463K -422K -54.35M -805K -5.44M -2.13M -27.22M -2.14M -2.09M -90.75M -383K -275K -239K -224K -204K -26.27M -389K -2.63M -1.03M -13.15M -1.03M -1.01M -43.86M
Net Debt 1.27M 915K 793K 743K 678K 87.29M 1.29M 8.74M 3.42M 43.71M 3.44M 3.36M 146M 1.5M 1.08M 934K 875K 798K 103M 1.52M 10.29M 4.02M 51.49M 4.05M 3.96M 172M
Logo Pharmadrug Inc.
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third-party validated potential for the treatment of infectious diseases and rare cancers. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions. It also owns 100% of SecureDose Synthetics Inc. a pharmaceutical research and development company focused on the development of synthetic formulations of existing drugs for potential commercialization and distribution.
Employees
-
Date Price Change Volume
26-08-11 US$0.005560 -19.42% 9,420
26-08-07 US$0.006900 +36.36% 5,000
26-08-06 US$0.005060 -41.16% 140,046
26-08-05 US$0.008600 +16.22% 5,000